Antibody drug conjugates: hitting the mark in pancreatic cancer?

Authors:
Wittwer NL; Brown MP; Liapis V; Staudacher AH.

Journal:
J Exp Clin Cancer Res

Publication Year: 2023

DOI:
10.1186/s13046-023-02868-x

PMCID:
PMC10598980

PMID:
37880707

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Exp Clin Cancer Res

Abbreviation: J Exp Clin Cancer Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Neoplasms

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
ABCB1 overexpression through locus amplification represents an actionable target to combat paclitax…
Bergonzini C; Gregori A; Hagens TMS and 13 more (2024) - Transparency Score: 4/6
A complex of cadherin 17 with desmocollin 1 and p120-catenin regulates colorectal cancer migration …
Bartolomé RA; Pintado-Berninches L; Martín-Regalado Á and 7 more (2024) - Transparency Score: 3/6
A novel PDPN antagonist peptide CY12-RP2 inhibits melanoma growth via Wnt/β-catenin and modulates t…
Feng C; Yu A; Wang Z and 9 more (2024) - Transparency Score: 3/6
A tumor suppressor protein encoded by circKEAP1 inhibits osteosarcoma cell stemness and metastasis …
Zhang Y; Liu Z; Zhong Z and 4 more (2024) - Transparency Score: 3/6
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram com…
Meraz-Torres F; Niessner H; Plöger S and 12 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Financial supportThis work was supported by a grant from Pankind, The Australian Pancreatic Cancer Foundation, Health Services Charitable Gifts Board (Adelaide, SA), and AusHealth Pty Ltd. Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

Evidence found in paper:

"Financial support This work was supported by a grant from Pankind, The Australian Pancreatic Cancer Foundation, Health Services Charitable Gifts Board (Adelaide, SA), and AusHealth Pty Ltd."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025